摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-8-methoxy-1-methyl-4,5-dihydro-2H-benzo[e]indazol-2-yl)-2-hydroxyethan-1-one

中文名称
——
中文别名
——
英文名称
1-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-8-methoxy-1-methyl-4,5-dihydro-2H-benzo[e]indazol-2-yl)-2-hydroxyethan-1-one
英文别名
1-[7-[[5-Chloro-4-(2-propan-2-ylsulfonylanilino)pyrimidin-2-yl]amino]-8-methoxy-1-methyl-4,5-dihydrobenzo[e]indazol-2-yl]-2-hydroxyethanone;1-[7-[[5-chloro-4-(2-propan-2-ylsulfonylanilino)pyrimidin-2-yl]amino]-8-methoxy-1-methyl-4,5-dihydrobenzo[e]indazol-2-yl]-2-hydroxyethanone
1-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-8-methoxy-1-methyl-4,5-dihydro-2H-benzo[e]indazol-2-yl)-2-hydroxyethan-1-one化学式
CAS
——
化学式
C28H29ClN6O5S
mdl
——
分子量
597.094
InChiKey
HSCSBODZXPHWFM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    41
  • 可旋转键数:
    8
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    157
  • 氢给体数:
    3
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor
    作者:Raghavendra Achary、Gangadhar Rao Mathi、Dong Ho Lee、Chang Soo Yun、Chong Ock Lee、Hyoung Rae Kim、Chi Hoon Park、Pilho Kim、Jong Yeon Hwang
    DOI:10.1016/j.bmcl.2017.03.073
    日期:2017.5
    In this study, a series of novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety was described for ALK inhibitor. The pyrazole, imidazole, 1,2,4-triazole, piperazine and phenanthridine moieties were employed at the 2-position of pyrimidine. Among the compounds synthesized, 28, 29, 36, and 42 showed promising anti-ALK activities in enzymatic- and cell-based assays. In vivo H3122 xenograft model study showed that compound 29 effectively suppressed ALK-driven tumor growth, similar to the extent of ceritinib, suggesting that it could be used for a novel ALK inhibitor development. (C) 2017 Published by Elsevier Ltd.
查看更多